[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-144961-105":59,"doc-detail-144961-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-prevalence-of-mismatch-repair-deficiency-in-ovarian-cancer-a-systematic-review-and-meta-analysis","The prevalence of mismatch repair deficiency in ovarian cancer - A systematic review and meta-analysis","","Ovarian cancer has poor survival and often presents late, creating demand for innovative approaches. Checkpoint inhibitors show strong efficacy in mismatch repair deficient (MMRd) cancers, but their application in ovarian cancer is constrained by limited prevalence data. This systematic review and meta-analysis, conducted using PRISMA guidelines, estimates MMRd prevalence across studies and summarizes evidence on immunohistochemistry and microsatellite instability results, heterogeneity, quality, and clinical implications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-prevalence-of-mismatch-repair-deficiency-in-ovarian-cancer-a-systematic-review-and-meta-analysis/144961/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-prevalence-of-mismatch-repair-deficiency-in-ovarian-cancer-a-systematic-review-and-meta-analysis/144961.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-20","2026-08-26",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this study?","Question",{"text":112,"@type":113},"To conduct a systematic review and meta-analysis estimating the prevalence of mismatch repair deficient (MMRd) ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies identified and selected?",{"text":117,"@type":113},"Studies were found through electronic searches of Medline, Embase, Cochrane CENTRAL, and Web of Science, followed by citation searching; studies not written in English were excluded and each study was reviewed by at least two independent reviewers.",{"name":119,"@type":110,"acceptedAnswer":120},"What prevalence estimates were reported for MMRd in ovarian cancer?",{"text":121,"@type":113},"Overall MMRd proportions were estimated as 6.7% by immunohistochemistry (IHC) and 10.4% by microsatellite instability (MSI) analysis, with MMRd reported across epithelial histotypes and most common in endometrioid ovarian cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},144961,1787713469,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":129,"read_time":144},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Edinburgh Research Explorer  \nThe prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta‐analysis  \nCitation for published version:  \nAtwal, A, Snowsill, T, Dandy, MC, Krum, T, Newton, C, Evans, DG, Crosbie, EJ & Ryan, NAJ 2022, 'The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta‐analysis', International Journal of Cancer, vol. 151, no. 9, pp. 1626-1639. [https://doi.org/10.1002/ijc.34165](https://doi.org/10.1002/ijc.34165)  \nDigital Object Identifier (DOI):  \n10.1002/ijc.34165  \nLink:  \nLink to publication record in Edinburgh Research Explorer  \nDocument Version:  \nPublisher's PDF, also known as Version of record  \nPublished In:  \nInternational Journal of Cancer  \nGeneral rights  \nCopyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.  \nTake down policy  \nThe University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please [contact openaccess@ed.ac.uk](contact openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.  \nDownload date: 25. Aug. 2026  \nReceived: 8 March 2022 Revised: 22 April 2022 Accepted: 11 May 2022  \nDOI: 10.1002/ijc.34165  \nTU MOR MARK E RS AND S IG NATU RES  \nThe prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis  \nAmit Atwal1 | Tristan Snowsill2  | Marcus Cabrera Dandy3 | Thomas Krum1 | Claire Newton4 | Dafydd Gareth Evans5  | Emma J. Crosbie6  | Neil A. J. Ryan4,7   \n1Clinical Medical School, University of Bristol, Bristol, UK  \n2Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK  \n3The Lancashire Women's and Newborn Centre, Burnley General Hospital, East Lancashire, UK  \n4Department of Obstetrics and Gynaecology, St. Michaels Hospital, Bristol, UK  \n5Division of Evolution and Genomic Medicine, St. Mary's Hospital, University of Manchester, Manchester, UK  \n6Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St. Mary's Hospital,  \nManchester, UK  \n7The Academic Women's Health Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK  \nCorrespondence  \nNeil A. J. Ryan, Research Room, Level D, St. Michaels Hospital, Bristol, UK.  \nEmail: [neil.ryan@bristol.ac.uk](neil.ryan@bristol.ac.uk)  \nFunding information  \nNIHR, Grant/Award Number: NF-SI- 0513-10076; NIHR Advanced Fellowship, Grant/Award Number: NIHR300650; NIHR Manchester Biomedical Research Centre, Grant/Award Number: IS-BRC-1215-20007  \nAbstract  \nOvarian cancer (OC) is the least survivable gynecological malignancy and presents late. Five-year survival for OC is around 45% increasing the need for innovative treatments. Checkpoint inhibitors have shown significant clinical efficacy in mismatch repair deficient (MMRd) cancers and could be a powerful treatment in OC. However, their application in OC is limited due to the lack of data on the prevalence of MMRd. The aim of our study was to conduct a systematic review of the literature and metaanalysis to provide an accurate estimate of the prevalence of MMRd in OC. We followed PRISMA guidelines throughout. Studies were identified by electronic searches of Medline, Embase, Cochrane CENTRAL and Web of Science followed by citation searching. Studies not written in English were excluded. All studies were reviewed by at least two independent reviewers. Proportions of test positivity were calculated by random and fixed-effects meta-analysis models. I2 score was used to assess heterogeneity across studies. In total 54 studies were in","cbCaig1JT3Fu8V5P","https://ap.wps.com/l/cbCaig1JT3Fu8V5P","pdf",1360066,15,"English","# Abstract\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What is the main purpose of this study?\",\"answer\":\"To conduct a systematic review and meta-analysis estimating the prevalence of mismatch repair deficient (MMRd) ovarian cancer.\"},{\"question\":\"How were studies identified and selected?\",\"answer\":\"Studies were found through electronic searches of Medline, Embase, Cochrane CENTRAL, and Web of Science, followed by citation searching; studies not written in English were excluded and each study was reviewed by at least two independent reviewers.\"},{\"question\":\"What prevalence estimates were reported for MMRd in ovarian cancer?\",\"answer\":\"Overall MMRd proportions were estimated as 6.7% by immunohistochemistry (IHC) and 10.4% by microsatellite instability (MSI) analysis, with MMRd reported across epithelial histotypes and most common in endometrioid ovarian cancer.\"}]","The prevalence of mismatch repair deficiency in ovarian cancer - A systematic review and meta-analysis | PDF",38]